FIGURE 1. Model for Augmented T-cell Activity Mediated by Inhibition of LAG-3 and PD-1 (Courtesy, Bristol-Myers Squibb; BMS-986016 Investigator Brochure, Appendix C).
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RATIONALE AND BACKGROUND INFORMATION
Glioblastoma is the most common primary malignancy of the brain, and the prognosis with conventional therapy is poor, with a median survival of only 14.6 mo after standard chemotherapy and radiation. 1 Recurrent glioblastoma treatment lacks high-quality evidence supporting its effectiveness.
Many years of study into the microenvironment of diffuse gliomas has shown that these lesions produce immunosuppressive factors, allowing these lesions to continue to proliferate unchecked, 2 despite many having an influx of immune cells. 3 To enhance immune responses to malignant tumors, investigators have recently developed monoclonal antibodies that target and inactivate immunosuppressive pathways.
Programmed death 1 (PD-1) is a T-cell surface immunosuppressive receptor; it is activated by programmed death ligand 1 and 2 (PD-L1 and PD-L2). 4 PD-L1 is upregulated in the tumor microenvironment of many tumors, and engagement of this ligand with its receptor, PD-1, reduces the cellular immune response within the tumor microenvironment. 4, 5 Targeting of the immunosuppressive checkpoint, PD-1, has provided initial evidence that immune therapy can be applied successfully in other cancers. Nivolumab, a monoclonal antibody targeting PD-1, was found to be efficacious and approved 6 for advanced melanoma, as was pembrolizumab, another PD-1 inhibitor. 7 Lymphocyte activation gene 3 (LAG-3) is another checkpoint present on activated T cells. 8 LAG-3 and PD-1 are co-expressed on the surface of tumor infiltrating T-cells in ovarian cancer and glioblastoma patients, and these markers denote poorly functional CD8+ T effector cells. 9, 10 The efficacy of single agent checkpoint inhibition may be limited by compensatory upregulation of other checkpoints, and this may be overcome by using combinations of checkpoint inhibitors (Figure 1 ).
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For the past few years, there has been widespread belief that checkpoint inhibitors, such as nivolumab and anti-LAG-3 therapy, could effectively target immunosuppression in the glioblastoma microenvironment, just as they have done in other systemic tumors. Preclinical models have supported this argument, with murine anti-PD-1, anti-PD-L1, and multicheckpoint inhibitor treatments demonstrating their efficacy by increasing overall survival in murine models of gliomas. [12] [13] [14] Yet, the successes of these therapeutics in treating diffuse glioma in humans are not guaranteed for numerous reasons. Most preclinical models rely on the murine immune system, which is very different from the human immune system. 15 Human and nonhuman models have differing cytokine profiles and dynamics for cell infiltration and inflammation patterns. Accordingly, the results of these murine studies cannot be automatically applied to human patients.
Additionally, even in the successful trials of these checkpoint inhibitors in other cancers, these treatments seem to only be effective in a small subset of patients. 16 Immune phenotyping has been attempted during checkpoint inhibitors trials in other cancers. 17 To date, none of these studies has yielded an accurate way to predict an immune reaction in the brain in response to checkpoint inhibition. 18 The evaluation of an immune response in glioblastoma is further complicated by the unique microenvironment of the brain. We have shown that immune cells can infiltrate the glioblastoma microenvironment, 19 ,20 yet further research is necessary to determine if systemically administered checkpoint inhibitors impact the tumor microenvironment and evoke an immune effect. To be comprehensive, such an analysis needs to include the measurement of cytokine expression in the immune microenvironment.
Local cytokine expression has not been evaluated in glioblastoma patients undergoing checkpoint inhibition, even though there is evidence that inflammatory cytokines could signal an effective response to checkpoint inhibitors. A recent study in mice has shown that PD-1 blockade leads to an upregulation of interferon gamma (IFNg) production in circulating T lymphocytes responding to an infection. 21 This agrees with previous research that shows that PD-L1 blockade upregulated IFNg production from T cells co-cultured with glioma tumor cells in vitro. 22 Anti-PD-1 therapy has also been shown to increase IFNg expression in the tumor microenvironment in a preclinical model of adoptive cell transfer. 23 Further, in recurrent glioblastoma patients, there is evidence that regulatory T cells in the systemic circulation of these patients release increasing amounts of IFNg in response to nivolumab. 24 Our plan is to collect an unprecedented set of matched longitudinal samples directly from the tumor microenvironment of glioblastoma patients before and after treatment with a checkpoint inhibitor to determine if this systemic treatment has a local neuroinflammatory effect. We will be able to use the results of this data collection to better predict how the brain might react to immune therapeutics.
STUDY GOALS AND OBJECTIVES
Primary Goals 1) To determine the proportion of patients who have a measurable increase of IFNg levels in the brain tumor tissue after their first dose of nivolumab as compared to the pretreatment baseline as measured by cerebral microdialysis, 2) To evaluate the safety and feasibility of using brain tumor microdialysis to monitor response to immune modulators in patients with recurrent glioblastoma, and 3) To evaluate the safety of the combination of nivolumab and anti-LAG-3 antibody treatment.
Secondary Goals 1)
To determine the change in IFNg production within the tumor microenvironment and in the rest of the body before and after therapy with nivolumab;
2) To evaluate the histologic response of the immune microenvironment of brain tumor tissue to the first dose of nivolumab; 3) To evaluate the clinical response (progression free survival, overall survival) of recurrent glioblastoma patients to treatment with BMS-986016 and nivolumab; 4) To describe the difference in survival between responders and nonresponders; 5) To examine the differences in the immune cells and secreted factors of the tumor environment as compared to the immune cells and secreted factors of the cerebral spinal fluid (CSF), blood, and bone marrow in response to this treatment.
STUDY DESIGN
This protocol is an open-label single-armed pilot study of the investigational off-label use of nivolumab and BMS-986016 in recurrent glioblastoma patients.
Study Populations
• Eighteen or older, with first recurrence of their previously treated glioblastoma (see Table 1 for full Inclusion and Exclusion Criteria).
• Accrual ceiling will be 15.
• Patients will be recruited to the NIH Clinical Center in Bethesda, MD.
• Target of 10 completed patients.
• Withdrawals which do not complete the initial study procedures will be replaced up to the accrual ceiling of 15 patients (see Table 2 for Criteria for Withdrawal from Study).
METHODOLOGY
Patients will undergo a surgical procedure that includes stereotactic needle biopsy to confirm the diagnosis of recurrent glioblastoma ( Figure 2 -study day 1). Any patient whose diagnosis of recurrent glioblastoma cannot be confirmed on frozen section will be removed from the study and replaced.
Following this confirmation, 2 microdialysis catheters will be implanted: one into the tumor and one into the surrounding brain ( Figure 3) . A lumbar intrathecal catheter will also be inserted to obtain serial samples of CSF after surgical biopsy. Finally, a bone marrow biopsy will be performed when possible. We will allow the inflammatory response to catheter implantation to subside by waiting 2 d before obtaining the baseline microdialysis and CSF samples. On study day 3, we will administer 240 mg of the PD-1 inhibitor, nivolumab. We will then obtain samples every 6 h from the microdialysis catheters. We will also obtain daily research blood samples and CSF. On study day 8, we will remove the microdialysis catheters and lumbar intrathecal catheter and perform a maximally safe surgical resection of the recurrent glioblastoma tumor. A second bone marrow biopsy will also be performed when possible. We will continue to enroll patients until we have 10 patients who have completed this initial monitoring period and surgical resection. On day 17 of the trial, each patient will receive 240 mg of nivolumab and 80 mg of an anti-LAG-3 antibody, BMS-986016. They will be treated with nivolumab and BMS-986016 every 2 wk until tumor progression or until the patient experiences an immune mediated toxicity that prevents further treatment. A research blood sample will be taken prior to treatment at each appointment 2 wk.
DISCUSSION
Recent failed trials of immune therapies in glioblastoma highlight the need to better understand the glioblastoma microenvironment to explain why these immune therapies have been ineffective against this tumor type. Specifically, rindopepimut, a vaccine targeted at the epidermal growth factor variant III, failed to improve progression-free survival in newly diagnosed glioblastoma patients during a randomized phase III trial, even though it demonstrated great initial promise in a phase II study. 25 Additionally, nivolumab did not show efficacy as a single agent in recurrent glioblastoma when compared to bevacizumab in a randomized study. 26, 27 Without efforts to better understand these failures, we are doomed to repeat them in the future.
If successful, this trial could lead to a new way to determine whether a patient will respond to immune therapy. Our longitudinal sampling process has broad applicability to different Subjects must be withdrawn from the study at any time for the following reasons:
1. Subject's prerogative: The subject desires to discontinue participation in this study 2. Investigator's prerogative: The subject is unwilling or unable to comply with the protocol 3. The biopsy indicates that the patient does not have a true pathological recurrence of their tumor 4. The patient experiences a grade 3 or 4 toxicity during phase 1 of the trial which precludes the completion of the intensive care unit monitoring period 5. The patient experiences a toxicity consistent with the nivolumab prescribing information that requires discontinuation of nivolumab. Such toxicities will be deemed sufficient to discontinue both nivolumab and BMS-986016. Specifically, these toxicities are: a. Immune-mediated pneumonitis: grade 3 or 4 immune-mediated pneumonitis will prompt automatic discontinuation of study drugs b. Immune-mediated colitis: grade 4 immune-mediated colitis will prompt automatic discontinuation of study drugs c. Immune-mediated hepatitis: grade 3 or 4 immune-mediated hepatitis will prompt automatic discontinuation of study drugs d. Immune-mediated endocrinopathies: grade 4 immune-mediated hypophysitis; grade 3 or 4 immune-mediated adrenal insufficiency; and grade 4 hyperglycemia will prompt automatic discontinuation of study drugs. Additionally, thyroid function will be followed, and thyroid hormone replacement will be given as needed e. Immune-mediated nephritis and renal dysfunction: grade 4 serum creatinine elevation will prompt automatic discontinuation of study drugs f. Immune-mediated skin adverse reactions: grade 4 rash will prompt automatic discontinuation of study drugs g. Immune-mediated encephalitis: grade 4 encephalitis will prompt automatic discontinuation of study drugs h. Infusion reactions: grade 3 or 4 infusion reactions will prompt automatic discontinuation of study drugs i. In addition to the above, due to the report of myocarditis in 1 patient on the combination of BMS-986016 and nivolumab, grade 4 myocarditis will prompt automatic discontinuation of study drugs
FIGURE 2. Study schematic, demonstrating intensive immune monitoring of trial patients.
immune therapeutics including checkpoint inhibition, adoptive cell therapy, and tumor vaccines. Once our pilot data have been validated, we could improve the therapeutic index of our immunotherapeutic clinical trials by enriching treatment groups for patients that show early signs of response. Conversely, patients who do not demonstrate markers of early response could be spared further ineffective therapy and be offered a different therapy based on the dynamic changes in their tumor microenvironment. Beyond our primary objectives, we also believe that this pilot trial has the potential to answer many burning questions. Potential secondary gains could be a better understanding of how CSF samples reflect changes in the immune microenvironment of the brain -is there a reliable relationship between cytokine levels in the interstitial fluid and CSF, or are they completely different and unrelated? What is the relationship between the immune cell populations in the CSF to those found in multiplex IHC in the tumor and surrounding brain? Are there serum markers that predict intracranial inflammation better than CSF markers do? Is the timeline of response of these markers in the various compartments -microdialysate, CSF, and serum -similar or different after systemic immune stimulation?
While we feel that this protocol will provide critical information for the treatment of brain tumors, we also feel that the study has the potential to create generalizable knowledge that will have a high impact in the scientific community. This trial presents an opportunity to reinvent how we measure neuroinflammation.
TRIAL STATUS
At the time of manuscript submission, the status of the trial is recruiting. 
SAFETY CONSIDERATIONS
Our trial design includes rigorous safety evaluations, including an in-depth review after each of the first 3 patients by a Safety Monitoring Committee. If it is determined at any point that performance of cerebral microdialysis for cytokines presents an undue risk to our patients, the pilot trial will be halted. At that time, the pilot would be reassessed and only reopened using less invasive means to obtain biomarkers of an immune response. These alternative means would include serial CSF collection and the use of pre-and posttreatment surgical specimens to determine pathological response.
The risk of placement and use of microdialysis catheters is reasonable in this patient group. The MD 71 microdialysis catheter has been used in multiple recent trials in glioma patients without any associated morbidity. [28] [29] [30] The stereotactic biopsy performed as a part of the microdialysis implantation surgery carries a 1% risk of symptomatic hemorrhage. 31 In clinical trials using nivolumab for other indications, the most common adverse events (graded using the Common Terminology Criteria for Adverse Events), regardless of causality, were fatigue, decreased appetite, diarrhea, nausea, cough, dyspnea, constipation, vomiting, rash, pyrexia, and headache. Common treatment-related adverse events included fatigue, rash, diarrhea, pruritus, decreased appetite, and nausea. Serious adverse effects were rare and included grade 3 or 4 pneumonitis, sarcoidosis, and elevated alanine aminotransferase levels.
While patients are at home, they will be instructed to contact us for any suspected adverse events. Generally, for any reported new symptom or adverse event, nonimmune events (such as disease progression) will be ruled out. If the adverse event is deemed to be related to nivolumab or BMS-986016, the side effects will be generally managed with administration of high-dose (2-4 mg/kg prednisolone equivalent) corticosteroids followed by a tapered dose and interruption of nivolumab therapy.
FOLLOW-UP
The patients will undergo a magnetic resonance imaging every 4 wk to detect signs of recurrence/pseudoprogression. It has been our clinical practice at the NIH Clinical Center to consider tissue sampling in patients when imaging changes and steroid challenges do not clearly identify whether a patient has recurrence or pseudoprogression due to an inflammatory response to checkpoint inhibition. At the completion of enrollment, we will analyze the CSF, microdialysis fluid, and blood for immune markers by proteomic analysis. We will measure changes in immune markers in the various compartments (brain tumor, brain, blood, CSF, bone marrow) before and after each patient's first dose of nivolumab.
DATA MANAGEMENT AND STATISTICAL ANALYSIS Data Management
Research samples and data will be coded for storage and analysis. The codes will be maintained by the Principal Investigator and the study coordinator. Research data will not be used to make treatment decisions and will not be placed in the patient's chart.
Data and samples may be shared with collaborating laboratories at NIH or outside of NIH and/or submitted to NIH-designated repositories and databases. Coded data and samples will be shared with Bristol-Myers Squibb.
Statistical Analysis
The accrual ceiling for the study will be 15 patients with the target of 10 patients completing the study. Adequate patients will be recruited through an Institutional Review Board (IRB)-approved flyer. Table 3 indicates that a sample size of 10 subjects: (a) will have 94.5% power to reject the null hypothesis: P ≤ 0.1 when ≥6 subjects are found to have increased IFNg in 5 d after the treatment and (b) will have 93.0% power to reject the null hypothesis: P ≤ 0.4 when ≥9 subjects are found to have increased IFNg. Table 4 presents the 95% confidence limits for the observed binomial proportion 0.3 to 1.0 based on a sample size of 10 subjects. For a sample size of 10 subjects, if 7 subjects are observed with increased IFNg in 5 d, the interval of (0.35, 0.93) will have 95% probability to include the true proportion. 
QUALITY ASSURANCE
The Principal Investigator will ensure that:
• the protocol is being correctly followed, • changes to the protocol have been approved by the IRB, • accurate, complete, and current records are being maintained and are secure, • subject withdrawal or study failure is noted in the records, and • informed consent has been correctly documented.
Emmes (Rockville, Maryland) has been engaged by NINDS as the Contract Research Organization (CRO) to monitor this protocol. The PI/sponsor, via the CRO, will be responsible for providing adequate oversight of the investigation to ensure adequate protection of the rights, welfare, and safety of human subjects and the quality and integrity of the resulting data.
This protocol will undergo periodic review by the NINDS Quality Assurance Audit Committee. The protocol is a more than minimal risk study and will be monitored based on the agreed upon monitoring plan with the CRO, at least once yearly. Adverse events will be reported to the FDA and NIH Combined Neurosciences Institutional Review Board in accordance with federal guidelines.
EXPECTED OUTCOMES OF THE STUDY
Based on preclinical data, we expect to see a predictable increase in IFNg levels in the microdialysate after systemic treatment with a checkpoint inhibitor. However, we cannot know for sure that we will be able to accurately detect an increase in IFNg levels in recurrent glioblastoma patients by cerebral microdialysis. While IFNg has been reliably recovered by cerebral microdialysis in the past, 28 there is a paucity of studies evaluating the response of the human cerebral microenvironment to immune interventions. For this reason, we will not only perform proteomic testing on the microdialysate, but we will be analyzing CSF, serum, and biopsy samples by this method as well. In the CSF and serum samples, there will be no concerns about accuracy of recovery based on the size of the cytokine being evaluated relative to microdialysis catheter pore size. Finally, as outlined above, our systematic sampling of tissue both before and after treatment with checkpoint inhibitors gives us an additional method to test whether the tumor has, in fact, responded to systematic immune modulation. We will use paired comparisons between the number of cells in the tumor microenvironment expressing CD4, CD8, CD3, PD-1, PD-L1, and LAG-3 before and after treatment with nivolumab to determine whether an immune response has occurred.
For evaluation of treatment response in recurrent glioblastoma patients undergoing checkpoint blockade, recent results suggest a median survival of 9 to 10 mo for recurrent glioblastoma patients treated with checkpoint inhibition. 26, 27 Our study is not powered to detect a significant difference in survival between responders and nonresponders. Accordingly, descriptive statistics will be used to evaluate median survival of treated patients.
DURATION OF THE PROJECT
After enrollment of the first patient, we anticipate that it will take a period of 18 mo to complete enrollment of up to 15 patients, 10 of which will have completed phase 1, the inpatient portion of the study. Thereafter, we anticipate 6 mo for completion of initial biomarker analysis and statistical review. We plan to complete longitudinal biomarker analysis, survival analysis, and final statistical review at 24 mo after completion of enrollment.
PROJECT MANAGEMENT
See Table 5 for list and description of all staff associated with study.
ETHICS
This is a very demanding research protocol for patients. The additional surgical procedure introduces risk that the patients would not otherwise encounter in routine treatment of their disease. Given the risk, there is a concern that the study neurosurgeons could enroll patients who are not good surgical NEUROSURGERY VOLUME 84 | NUMBER 4 | APRIL 2019 | 951 NOB/NCI She will obtain informed consent from subjects enrolling in the study, and she will help with microdialysis sample collection and data analysis Gretchen C. Scott, BSN, RN SNB/NINDS She will organize outside medical records for review by the study team. In addition, she will record patient outcomes and adverse events that will be used in data and safety monitoring Christina Piper Hayes, M, CRNP SNB/NINDS She will obtain informed consent from subjects enrolling in the study, monitor for adverse events, perform study assessments according to her credentialed qualifications, and complete CRFs Sarah Benzo, BSN, RN SNB/NINDS She will organize outside medical records for review by the study team. In addition, she will record patient outcomes and adverse events that will be used in data and safety monitoring Christopher S. Hourigan candidates for the purposes of quickly completing enrollment. For this reason, if any patient has not been directly referred to the study neurosurgeons as a good candidate for surgical resection, the patient's medical record will need to be reviewed by an outside neurosurgeon for suitability as a surgical candidate prior to enrollment. Furthermore, subjects will be counseled that they do not have to participate in this study to receive surgery at the NIH Clinical Center. They may also prefer to receive evaluation and surgical treatment under the care of their own physicians at an outside facility. Screened patients will also be informed of other treatment trials, including those at the NIH Clinical Center, local academic centers, and private institutions. Capacity to consent will be determined at enrollment by the treating advanced medical practitioner. A lack of consent capacity due to cognitive impairment will preclude the patient from being fully enrolled into the trial (see Table 1 ). The NIH Ability to Consent Assessment Team will be consulted if there are any concerns regarding a patient's capacity to consent. Participants will receive a verbal explanation of the purposes, procedures, and risks of the study and of their rights as research participants. Participants will have the opportunity to review the written consent form and ask questions regarding this study prior to enrollment. 
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